The gut microbial metabolite butyrate can promote anti‐tumour therapeutic efficacy through inhibitor of DNA binding 2‐dependent modulation of CD8+ T cell immunity, suggesting that gut microbial metabolites may be effective as part of cancer therapy.218. This evidence concerns the gene CD8A and neoplasm.